IT1400309B1 - ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE. - Google Patents

ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.

Info

Publication number
IT1400309B1
IT1400309B1 ITRM2010A000230A ITRM20100230A IT1400309B1 IT 1400309 B1 IT1400309 B1 IT 1400309B1 IT RM2010A000230 A ITRM2010A000230 A IT RM2010A000230A IT RM20100230 A ITRM20100230 A IT RM20100230A IT 1400309 B1 IT1400309 B1 IT 1400309B1
Authority
IT
Italy
Prior art keywords
xanthin
association
calcium antagonists
oxidase
inhibitors
Prior art date
Application number
ITRM2010A000230A
Other languages
Italian (it)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Priority to ITRM2010A000230A priority Critical patent/IT1400309B1/en
Priority to PCT/EP2011/057326 priority patent/WO2011141381A1/en
Priority to TW100116122A priority patent/TW201206433A/en
Publication of ITRM20100230A1 publication Critical patent/ITRM20100230A1/en
Application granted granted Critical
Publication of IT1400309B1 publication Critical patent/IT1400309B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
ITRM2010A000230A 2010-05-10 2010-05-10 ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE. IT1400309B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITRM2010A000230A IT1400309B1 (en) 2010-05-10 2010-05-10 ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.
PCT/EP2011/057326 WO2011141381A1 (en) 2010-05-10 2011-05-06 Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
TW100116122A TW201206433A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and calcium antagonists and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000230A IT1400309B1 (en) 2010-05-10 2010-05-10 ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.

Publications (2)

Publication Number Publication Date
ITRM20100230A1 ITRM20100230A1 (en) 2011-11-11
IT1400309B1 true IT1400309B1 (en) 2013-05-24

Family

ID=42753374

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000230A IT1400309B1 (en) 2010-05-10 2010-05-10 ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.

Country Status (3)

Country Link
IT (1) IT1400309B1 (en)
TW (1) TW201206433A (en)
WO (1) WO2011141381A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016155815A1 (en) 2015-04-01 2016-10-06 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (en) * 1982-03-11 1991-12-09 Pfizer CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
DE122008000051I1 (en) 1990-11-30 2009-02-05 Teijin Ltd 2-ARYLTHIAZOL DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
GT199800127A (en) 1997-08-29 2000-02-01 THERAPEUTIC COMBINATIONS.
HU229405B1 (en) 1998-06-19 2013-12-30 Teijin Pharma Ltd Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and processes for the preparation thereof
SK285863B6 (en) 1998-07-10 2007-10-04 Novartis Ag Pharmaceutical combination composition comprising the AT1-antagonist valsartan and amlodipine
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
EP2101761A4 (en) 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A Methods for preserving renal function using xanthine oxidoreductase inhibitors

Also Published As

Publication number Publication date
TW201206433A (en) 2012-02-16
WO2011141381A1 (en) 2011-11-17
ITRM20100230A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
CY2020025I1 (en) BETA-LACTAMASE INHIBITORS
SMT201600135B (en) NEW INHIBITORS OF THE S-NITROSOGLUTATION RIDUTTASI
LTPA2019506I1 (en) Non-nucleoside reverse transcriptase inhibitors
SMT201600021B (en) NEW CHINOLINA COMPOUNDS REPLACED AS INHIBITORS OF S-NITROSOGLUTATION AND REDUCTASE
SMT201600023B (en) PYRIDAZINONIC COMPOUNDS AND THEIR USE AS INHIBITORS OF DAAO
DK2536722T3 (en) BICYCLIC RELATIONS AND THEIR USE AS DUAL-C-SRC / JAK INHIBITORS
BR112013012078A2 (en) nampt and rock inhibitors
ECSP13012394A (en) NEW FORMS OF MODIFIED RELEASE DOSAGE OF AN XANTINA OXIDORREDUCTASA INHIBITOR OR XANTINA OXIDASA INHIBITORS
BRPI0915231A2 (en) kinase inhibitor compounds and methods of use
BRPI1012333A2 (en) atropisomers of 2-purinyl-3-tolyl-quinazolinones derivatives and methods of use
ECSP12012034A (en) PCSK9 ANTAGONISTS
BR112013025353A2 (en) combinations of akt and erlotinib inhibitor compounds and methods of use
CO6781493A2 (en) Faah Inhibitors
DK3178818T3 (en) PYRAZOLYLQUINOXALINKINASE INHIBITORS
DOP2012000114A (en) BROMODOMINIUM INHIBITOR OF BENZODIAZEPINA
EP2480576A4 (en) Antagonists of pcsk9
DOP2011000397A (en) NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10A
BR112013006016A2 (en) azabenzothiazole compounds, compositions and methods of use
SMT201700064B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
BRPI1014544A2 (en) anti-il-17f anticorpors and methods of use
BRPI0911332A2 (en) compositions and use of epas1 inhibitors
BRPI0922344A2 (en) tfpi inhibitors and methods of use
BR112013010331A2 (en) creped adhesive compositions and methods of use of such compositions
SMT201500071B (en) Antimalarial agents that are inhibitors of dihydro-orotate dehydrogenase